Willing to undergo hepatitis C treatment in a sample of injection drug users in Toronto, Canada

被引:13
作者
Fischer, B
Vasdev, S
Haydon, E
Baliunas, D
Rehm, J
机构
[1] Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Ottawa, Ottawa, ON, Canada
[4] Res Inst Addict, Zurich, Switzerland
来源
PRESSE MEDICALE | 2005年 / 34卷 / 17期
关键词
D O I
10.1016/S0755-4982(05)84158-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The majority of prevalent and incident hepatitis C (HCV) infections in Canada are related to injection drug use (IDU), thus positioning injection drug users (IDUs) as a critical population to be targeted for HCV treatment. Little research has been undertaken in order to discover the willingness of IDUs to receive HCV treatment, however. Methods The study sample was part of the Opican (illicit CIPIoid use in CANada) cohort study of illicit opioid and other drug users in five Canadian cities. Results Data were collected from a sub-sample of 50 HCV-positive IDUs in Toronto. Four fifths of participants indicated general willingness to participate in HCV treatment. Two conditional treatment questions led to significant decreases in treatment willingness (potential treatment side effects and requirement of addiction treatment). Conclusion The majority of IDUs in this sample indicated willingness to participate in HCV treatment, yet the particular needs and situations of this marginalized population have to be considered and addressed for responsive HCV treatment delivery.
引用
收藏
页码:1209 / 1212
页数:4
相关论文
共 22 条
  • [1] Treatment of hepatitis C infection in injection drug users
    Backmund, M
    Meyer, K
    Von Zielonka, M
    Eichenlaub, D
    [J]. HEPATOLOGY, 2001, 34 (01) : 188 - 193
  • [2] Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users
    Edlin, BR
    Kresina, TF
    Raymond, DB
    Carden, MR
    Gourevitch, MN
    Rich, JD
    Cheever, LW
    Cargill, VA
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 : S276 - S285
  • [3] Prevention and treatment of hepatitis C in injection drug users
    Edlin, BR
    [J]. HEPATOLOGY, 2002, 36 (05) : S210 - S219
  • [4] Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
    Edlin, BR
    Seal, KH
    Lorvick, J
    Kral, AH
    Ciccarone, DH
    Moore, LD
    Lo, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) : 211 - 214
  • [5] Illicit opiold use in Canada:: Comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study)
    Fischer, B
    Rehm, J
    Brissette, S
    Brochu, S
    Bruneau, J
    El-Guebaly, N
    Noël, L
    Tyndall, M
    Wild, C
    Mun, P
    Baliunas, D
    [J]. JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2005, 82 (02): : 250 - 266
  • [6] Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach - The case study of Canada
    Fischer, B
    Haydon, E
    Rehm, J
    Krajden, M
    Reimer, J
    [J]. JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2004, 81 (03): : 428 - 447
  • [7] Canadian illicit opiate users' views on methadone and other opiate prescription treatment: An exploratory qualitative study
    Fischer, B
    Chin, AT
    Kuo, I
    Kirst, M
    Vlahov, D
    [J]. SUBSTANCE USE & MISUSE, 2002, 37 (04) : 495 - 522
  • [8] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982
  • [9] Hepatitis C virus transmission dynamics in injection drug users
    Hagan, H
    [J]. SUBSTANCE USE & MISUSE, 1998, 33 (05) : 1197 - 1212
  • [10] HUBER M, 2002, SUCHTTHERAPIE, V3, pS27